These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25388278)

  • 21. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors.
    Saleh NA
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Feb; 136 Pt C():1523-9. PubMed ID: 25459714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    Eur J Med Chem; 2010 Apr; 45(4):1387-94. PubMed ID: 20116899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanics analysis of inhibitor binding to HIV-1 protease.
    Sansom CE; Wu J; Weber IT
    Protein Eng; 1992 Oct; 5(7):659-67. PubMed ID: 1480620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetra-chloro-(bis-(3,5-dimethylpyrazolyl)methane)gold(III) chloride: An HIV-1 reverse transcriptase and protease inhibitor.
    Fonteh PN; Keter FK; Meyer D; Guzei IA; Darkwa J
    J Inorg Biochem; 2009 Feb; 103(2):190-4. PubMed ID: 19019450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
    Zhou Z; Madura JD
    Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fullerene-based inhibitors of HIV-1 protease.
    Strom TA; Durdagi S; Ersoz SS; Salmas RE; Supuran CT; Barron AR
    J Pept Sci; 2015 Dec; 21(12):862-70. PubMed ID: 26767741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors-In Silico Activity Prediction.
    Dąbrowska A; Pieńko T; Taciak P; Wiktorska K; Chilmonczyk Z; Mazurek AP; Stasiulewicz A
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
    Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
    J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Madura JD
    Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Segmental analysis of molecular surface electrostatic potentials: application to enzyme inhibition.
    Brinck T; Jin P; Ma Y; Murray JS; Politzer P
    J Mol Model; 2003 Apr; 9(2):77-83. PubMed ID: 12707800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Gago F
    Antiviral Res; 2006 Sep; 71(2-3):260-7. PubMed ID: 16872687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives.
    Mashino T; Shimotohno K; Ikegami N; Nishikawa D; Okuda K; Takahashi K; Nakamura S; Mochizuki M
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1107-9. PubMed ID: 15686922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A check on rational drug design: molecular simulation of the allosteric inhibition of HIV-1 reverse transcriptase.
    Mager PP
    Med Res Rev; 1997 May; 17(3):235-76. PubMed ID: 9127858
    [No Abstract]   [Full Text] [Related]  

  • 36. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
    Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase.
    Rao GS; Bhatnagar S
    J Biomol Struct Dyn; 2003 Oct; 21(2):171-8. PubMed ID: 12956603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1.
    Singh A; Yadav D; Yadav M; Dhamanage A; Kulkarni S; Singh RK
    Chem Biol Drug Des; 2015 Mar; 85(3):336-47. PubMed ID: 25055732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
    Xu Z; Guo J; Yang Y; Zhang M; Ba M; Li Z; Cao Y; He R; Yu M; Zhou H; Li X; Huang X; Guo Y; Guo C
    Eur J Med Chem; 2016 Nov; 123():309-316. PubMed ID: 27484516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.